Navigation Links
FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
Date:10/1/2009

rises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER, the Bayer Cross, and Mirena are registered trademarks of Bayer HealthCare Pharmaceuticals.

(1) van Eijkeren MA, Christiaens GC, Sixma JJ, Haspels AA. Menorrhagia: A review. Obstet Gynecol Surv 1989; 44:421.

(2) Mayo Clinic: http://www.mayoclinic.com/health/menorrhagia/DS00394/DSECTION=symptoms

(3) Bayer: data on file.

SOURCE Bayer HealthCare Pharmaceuticals


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
2. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
3. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
4. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
5. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
6. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
7. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
8. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
9. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
10. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
11. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... RIVERWOODS, Ill., June 10 As more and more employees ... a smaller and smaller percentage of them are actually signing ... the findings of the Spencer,s Benefits Reports 2009 ... COBRA in the 2008 plan year at companies covered by ...
... ARLINGTON, Va., June 10 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding publication of the Federal ... , , "Today,s report from the FTC ... forward on passage of legislation that brings affordable biogenerics ...
... RIVERSIDE, California and NUREMBERG, Germany, June 10 ,Ziehm Imaging ... and Drug,Administration (FDA) has given 510k clearance for the ... RFD, for marketing and,sales within the United States. Designed ... the Ziehm Vision RFD,mobile C-arm combines the latest flat-panel ...
... Corporation (Nasdaq: KNSY ) is scheduled to present ... 18, 2009. , , Joseph W. Kaufmann, Kensey ... at approximately 9:00 a.m. (ET). To hear the live ... . The presentation materials will also be available on ...
... bacteria,s structure, , WEDNESDAY, June 10 (HealthDay News) -- ... a vacation. , Now, researchers have figured out how ... coli, or ETEC -- are able to make ... or "fimbriae" to attach, or bind, to the intestinal ...
... 2009, the Institute for Quality and Efficiency in Health ... assessment of certain newer antidepressants. The project commissioned by ... the benefit of three agents, reboxetine, mirtazapine and bupropion ... German drug approval status. Interested parties and institutions may ...
Cached Medicine News:Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 2Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 3Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:Finding May Lead to Vaccine for Traveler's Diarrhea 2Health News:Preliminary report on antidepressants published 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: